James Niedel
CIK 1231092 · last filed 2017-06-29
James Niedel is a corporate insider who has filed 10 SEC Form 4 insider transactions across 3 companies since 2012. The most recent filing, for CMRX, was dated Jun 29, 2017. Across all open-market trades the lifetime net is +$31.4M, making them a net buyer over the disclosed history. 24 SEC filings were submitted jointly with Philippe O. Chambon.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
11 MADISON AVE
NEW YORK, NY 10010
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CHIMERIX INC (CMRX) Delisted | Director | 1,046,082 | $8.54 | $8.93M | -$41.41M | 7 | 2017-06-29 |
| Relypsa Inc (RLYP) Delisted | 1,924,626 | — | — | $16.37M | 1 | 2013-11-20 | |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 2,244,126 | — | — | $56.47M | 1 | 2012-07-26 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-29 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-28 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-24 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-09-11 | CHIMERIX INC (CMRX) Delisted | Mixed | −497,312 | -$27.96M | EDGAR |
| 2014-03-20 | CHIMERIX INC (CMRX) Delisted | Other (J) | −700,000 | $0 | EDGAR |
| 2013-11-20 | Relypsa Inc (RLYP) Delisted | Mixed | +16,919,120 | $16.37M | EDGAR |
| 2013-10-23 | CHIMERIX INC (CMRX) Delisted | Sell (S) | −585,602 | -$9.08M | EDGAR |
| 2013-04-16 | CHIMERIX INC (CMRX) Delisted | Conv (C) | +2,410,551 | $0 | EDGAR |
| 2012-07-26 | Durata Therapeutics, Inc. (DRTX) Delisted | Mixed | +24,227,512 | $56.47M | EDGAR |
| 2007-01-09 | — | Disp (D) | −381,336 | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.